What is the long-term growth potential of TTNP compared to its industry peers?

Titan Pharmaceuticals (TTNP) has shown some positive signs in terms of market sentiment and financial performance. The upward shift in the 20-day Simple Moving Average (SMA) suggests an increased buyer influence, potentially driving the stock price upwards in the near term. This indicates a change in market sentiment, which could be a positive indicator for long-term growth. Additionally, the company's partnership with Indegene and the ongoing Probuphine campaigns could contribute to future revenue streams.

However, it's important to note that TTNP has a negative Basic EPS and a high debt-to-equity ratio, indicating potential financial challenges. The industry peer comparison analysis would provide a more comprehensive understanding of TTNP's growth potential relative to its competitors. In conclusion, while there are some positive indicators, further evaluation of the company's financial health and industry position is necessary to determine its long-term growth potential.